摘要
目的 观察长期吸入沙美特罗/氟替卡松及噻托溴铵治疗稳定期慢性阻塞性肺疾病(COPD)患者的疗效.方法 将95例稳定期COPD患者随机分为三组:A组吸入沙美特罗/氟替卡松和噻托溴铵;B组吸入沙美特罗/氟替卡松;C组吸入噻托溴铵.治疗半年,评估肺功能1秒钟用力呼气容积(FEV1)、FEV1与用力肺活量的比值与治疗满意度.疗效比较采用优势检验.结果 全部病例完成半年随访,吸入沙美特罗/氟替卡松和噻托溴铵可明显减缓肺功能的恶化,同时发现吸入沙美特罗/氟替卡松和噻托溴铵组有着明显的治疗满意度.结论 吸入沙美特罗/氟替卡松和噻托溴铵在改善症状方面优于噻托溴铵,具有较好的依从性.
Objective To observe therapeutic effects of inhaling salmeterol/fluticasone and tiotropium bromide for stable COPD patients. Methods Ninety-five cases of stable COPD patients were divided randomly into three groups, group A inhaling salmeterol/fluticasone and tiotropium bromide, group B inhaling salmeterol/fluticasone, group C inhaling tiotropium bromide. All were for half a year. Lung function(FEV1,FEV1/FVC) and AECOPD manifestations and therapeutic satisfaction were evaluated. Therapeutic effects were compared with advantage test. Results All follow-ups of half a year were completed. It was found that inhaling salmeterol/fluticasone and tiotropium bromide could decrease obviously worsening of lung function. And meanwhile there was more satisfactory therapy than another two groups.Conclusions Inhaling salmeterol/fluticasone is better than inhaling tiotropium bromide in improving symptoms and with better compliance.
出处
《中国实用医刊》
2010年第9期31-32,共3页
Chinese Journal of Practical Medicine
关键词
慢性阻塞性肺疾病
沙美特罗/氟替卡松
噻托溴铵
Chronic obstructive pulmonary disease,Salmeterol/fluticasone
Tiotropium bromide
